As of August 2016, what was the market capitalisation of the company that developed the drug Losmapimod?
Losmapimod: Losmapimod (GW856553X) is a drug developed by GlaxoSmithKline which acts as a selective inhibitor of the enzyme family known as p38 mitogen-activated protein kinases. GlaxoSmithKline:  As of August 2016 it had a market capitalisation of £81 billion (around $107 billion), the fourth largest on the London Stock Exchange.
£81 billion